Skip to content

Serotonin: all studies

Page 160 of 401: studies 1,591 to 1,600 of 4,004, newest first. Back to the serotonin overview

Research

Human Research on MDMA (3,4-Methylene- dioxymethamphetamine) Neurotoxicity: Cognitive and Behavioural Indices of Change

Neuropsychobiology 2000 A. C. Parrott 153 citations

Laboratory animals can develop serotonergic neurotoxicity after repeated doses of 3,4-methylenedioxymethamphetamine (MDMA) or ‘Ecstasy’. If similar neural damage occurs in humans, this may be evident in cognitive or behavioural impairments. In a review of the behavioural skills shown by drug-free recreational Ecstasy users, three aspects of cognitive performance are often affected: reduced...

Hallucinogenic drugs attenuate the subjective response to alcohol in humans

Human Psychopharmacology: Clinical and Experimental 2000 Sean P. Barrett, Jennifer Archambault, Marla Engelberg et al. 11 citations

This study investigated possible interactions between alcohol and hallucinogens in 22 lysergic acid diethylamide (LSD) and/or psilocybin users through retrospective structured interviews. Of those who had used LSD with alcohol, 86;7 per cent reported a complete blockade of subjective alcohol effects, while the remaining cases reported a diminished response. In addition, 60 per cent of...

α-Lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity

Neuroreport November 1, 1999 Norberto Aguirre, Meritxell Barrionuevo, Marı́a J. Ramı́rez et al. 89 citations

A single administration of 3,4-methylenedioxymetham-phetamine (MDMA, 20 mg/kg, i.p.), induced significant hyperthermia in rats and reduced 5-hydroxytryptamine (5-HT) content and [3H]paroxetine-labeled 5-HT transporter density in the frontal cortex, striatum and hippocampus by 40–60% 1 week later. MDMA treatment also increased glial fibrillary acidic protein (GFAP) immunoreactivity in the...

Cerebral 1H MRS alterations in recreational 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) users

Journal of Magnetic Resonance Imaging October 1, 1999 L. Chang, Thomas Ernst, C.s. Grob et al. 28 citations

3,4-Methylenedioxymethamphetamine (MDMA) is an illicit drug that has been associated with serotonergic axonal degeneration in animals. This study evaluates neurochemical abnormalities in recreational MDMA users. Twenty-two MDMA users and 37 normal subjects were evaluated with magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H MRS) in the mid-frontal, mid-occipital,...

Cerebral1H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, ?ecstasy?) users

Journal of Magnetic Resonance Imaging October 1, 1999 L. Chang, Thomas Ernst, Charles S. Grob et al. 109 citations

3,4-methylenedioxymethamphetamine (MDMA) is an illicit drug that has been associated with serotonergic axonal degeneration in animals. This study evaluates neurochemical abnormalities in recreational MDMA users. Twenty-two MDMA users and 37 normal subjects were evaluated with magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) in the mid-frontal,...

LSD and DOB: interaction with 5‐HT2A receptors to inhibit NMDA receptor‐mediated transmission in the rat prefrontal cortex

European Journal of Neuroscience September 1, 1999 Viktor L. Arvanov, Xiaofu Liang, Angelo Russo et al. 64 citations

Abstract Both the phenethylamine hallucinogen (–)‐1‐2,5‐dimethoxy‐4‐bromophenyl‐2‐aminopropane (DOB), a selective serotonin 5‐HT 2A,2C receptor agonist, and the indoleamine hallucinogen d ‐lysergic acid diethylamide (LSD, which binds to 5‐HT1A, 1B, 1D, 1E, 1F, 2A, 2C, 5, 6, 7, dopamine D 1 and D 2 , and α 1 and α 2 adrenergic receptors), but not their non‐hallucinogenic congeners, inhibited...

DOI: 10.1046/j.1460-9568.1999.00726.x (opens in new tab) Serotonin Hallucinogen Nmda receptor Pharmacology +8

The Acute Effect in Rats of 3, 4‐Methylenedioxyethamphetamine (MDEA, “Eve”) on Body Temperature and Long Term Degeneration of 5‐HT Neurones in Brain: A Comparison with MDMA (“Ecstasy”)

Pharmacology & Toxicology June 1, 1999 María Isabel Colado, Raquel Ena María Granados, Esther O’shea et al. 26 citations

Abstract: Administration of a single dose of the recreationally used drug 3, 4‐methylenedioxyethamphetamine (MDEA or “eve”) to Dark Agouti rats resulted in an acute dose‐dependent hyperthermic response. The peak effect and duration of hyperthermia of a dose of MDEA of 35 mg/kg intraperitoneally was similar to a dose of 3, 4‐methylenedioxymetham‐phetamine (MDMA or “ecstasy”) of 15 mg/kg...

Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.

Journal of Medicinal Chemistry November 5, 1998 Simon M. N. Efange, Deborah C. Mash, A B Khare et al. 33 citations

Five phenyl-substituted derivatives and analogues of 1,2,3,4,5, 6-hexahydroazepino[4,5-b]indole, 5, a major fragment of ibogaine (1), were synthesized and tested for binding to monoamine transporters, the NMDA receptor-coupled cation channel, and dopamine and opioid receptors. All five derivatives, 9 and 17a-d, displayed 8-10-fold higher affinity at the DA transporter than ibogaine and...

DOI: 10.1021/jm980156y (opens in new tab) Full text (opens in new tab) Drug discovery New compounds Novel compounds Synthesized +18

Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research

Pharmacopsychiatry July 1, 1998 Franz X. Vollenweider 131 citations

Recent research into the pharmacological mechanism of hallucinogens (LSD, psilocybin) and dissociative anesthetics (PCP, ketamine) suggest that multiple neurotransmitter systems are involved in drug-induced and possibly also in naturally occurring psychoses. Specifically, animal models suggest that a dysbalance between serotonin, glutamate, and dopamine in the limbic cortico-striato-thalamic...